Literature DB >> 16737674

NCCN Task Force Report: Bone Health and Cancer Care.

Richard L Theriault, J Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L Shapiro, Matthew Smith, Catherine H Van Poznak.   

Abstract

Higher incidences of osteoporosis and osteopenia are found in cancer patients, particularly in women receiving aromatase inhibitors or with chemotherapy-induced ovarian failure, or in men with prostate cancer and androgen deprivation therapy. Therefore, management of long-term bone health is emerging as an important aspect of comprehensive cancer care. Patients with cancer typically have a number of additional risk factors for osteoporosis that should prompt screening, regardless of patient age or sex. Maintaining bone health requires a broad knowledge base, including understanding underlying bone metabolism and how it is affected by both cancer itself and the drugs used to treat cancer, the effect of chemotherapy-induced menopause on bone health, bone markers and imaging techniques used to assess bone health, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the healthcare team may need to be involved in education and care of the patient. This report summarizes discussion of these and other issues regarding bone health and cancer care from the NCCN Bone Health and Cancer Care Task Force meeting in early 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16737674

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  12 in total

1.  AIs: implications for fractures in perimenopausal women with breast cancer.

Authors:  Beatrice J Edwards; Athena Samaras; June M McKoy; Simone Boyle; Charles L Bennett
Journal:  Community Oncol       Date:  2008-11-01

2.  Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer.

Authors:  Beatrice J Edwards; Dennis W Raisch; Veena Shankaran; June M McKoy; William Gradishar; Andrew D Bunta; Athena T Samaras; Simone N Boyle; Charles L Bennett; Dennis P West; Theresa A Guise
Journal:  Clin Cancer Res       Date:  2011-02-01       Impact factor: 12.531

3.  The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.

Authors:  Peter S Kirk; Tudor Borza; Vahakn B Shahinian; Megan E V Caram; Danil V Makarov; Jeremy B Shelton; John T Leppert; Ryan M Blake; Jennifer A Davis; Brent K Hollenbeck; Anne Sales; Ted A Skolarus
Journal:  BJU Int       Date:  2017-11-28       Impact factor: 5.588

4.  Factors associated with cancer-related fatigue in breast cancer patients undergoing endocrine therapy in an urban setting: a cross-sectional study.

Authors:  Xu Huang; Qingyuan Zhang; Xinmei Kang; Ying Song; Wenhui Zhao
Journal:  BMC Cancer       Date:  2010-08-23       Impact factor: 4.430

Review 5.  Cancer-associated bone disease.

Authors:  Sue A Brown; Theresa A Guise
Journal:  Curr Osteoporos Rep       Date:  2007-09       Impact factor: 5.096

6.  The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.

Authors:  Allan Lipton; Robert Uzzo; Robert J Amato; Georgiana K Ellis; Behrooz Hakimian; G David Roodman; Matthew R Smith
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

7.  Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.

Authors:  G J van Londen; S Perera; K T Vujevich; S M Sereika; R Bhattacharya; S L Greenspan
Journal:  Bone       Date:  2008-04-15       Impact factor: 4.398

8.  Patterns of bone density evaluation in a community population treated with aromatase inhibitors.

Authors:  Jennifer A Ligibel; A James O'Malley; Maxine Fisher; Gregory W Daniel; Eric P Winer; Nancy L Keating
Journal:  Breast Cancer Res Treat       Date:  2012-07-12       Impact factor: 4.872

Review 9.  Cancer treatment-related bone disease.

Authors:  Sue A Brown; Theresa A Guise
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2009       Impact factor: 1.807

10.  Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.

Authors:  Allan Lipton; Matthew R Smith; Georgiana K Ellis; Carsten Goessl
Journal:  Clin Med Insights Oncol       Date:  2012-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.